KR102550455B1 - 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 - Google Patents
아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 Download PDFInfo
- Publication number
- KR102550455B1 KR102550455B1 KR1020210095267A KR20210095267A KR102550455B1 KR 102550455 B1 KR102550455 B1 KR 102550455B1 KR 1020210095267 A KR1020210095267 A KR 1020210095267A KR 20210095267 A KR20210095267 A KR 20210095267A KR 102550455 B1 KR102550455 B1 KR 102550455B1
- Authority
- KR
- South Korea
- Prior art keywords
- fluoro
- methyl
- compound
- difluoro
- iodoanilino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
- C07C223/06—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Emergency Medicine (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230081877A KR20230098762A9 (ko) | 2020-07-22 | 2023-06-26 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/028575 WO2022018875A1 (ja) | 2020-07-22 | 2020-07-22 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
| KRPCT/JP2020/028575 | 2020-07-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230081877A Division KR20230098762A9 (ko) | 2020-07-22 | 2023-06-26 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220012195A KR20220012195A (ko) | 2022-02-03 |
| KR102550455B1 true KR102550455B1 (ko) | 2023-06-30 |
Family
ID=79729374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210095267A Active KR102550455B1 (ko) | 2020-07-22 | 2021-07-21 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
| KR1020230081877A Pending KR20230098762A9 (ko) | 2020-07-22 | 2023-06-26 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230081877A Pending KR20230098762A9 (ko) | 2020-07-22 | 2023-06-26 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Country Status (3)
| Country | Link |
|---|---|
| JP (4) | JPWO2022018875A1 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102550455B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022018875A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| AU2022312992A1 (en) * | 2021-07-21 | 2024-02-29 | Chugai Seiyaku Kabushiki Kaisha | Method for producing arylamide derivative |
| WO2023204259A1 (ja) * | 2022-04-20 | 2023-10-26 | 中外製薬株式会社 | がんの治療又は予防用医薬 |
| EP4551558A2 (en) * | 2022-07-08 | 2025-05-14 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
| JP2026522033A (ja) * | 2023-07-06 | 2026-07-03 | 華健未来(成都)科技股▲フン▼有限公司 | 芳香族アミド誘導体およびその使用 |
| WO2025063275A1 (ja) * | 2023-09-21 | 2025-03-27 | 中外製薬株式会社 | アリールアミド誘導体の製造方法 |
| AU2024417154A1 (en) * | 2024-01-01 | 2026-08-13 | Huajian Future (Chengdu) Technology Co., Ltd. | Aromatic hydrazide derivative and medical use thereof |
| WO2026098657A1 (zh) * | 2024-11-08 | 2026-05-15 | 先声再明医药股份有限公司 | 作为mek抑制剂的杂环化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028426A1 (ja) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| WO2006011466A1 (ja) | 2004-07-26 | 2006-02-02 | Chugai Seiyaku Kabushiki Kaisha | Mek阻害物質としての5-置換-2-フェニルアミノ-ベンズアミド類 |
| WO2014081024A1 (ja) | 2012-11-26 | 2014-05-30 | 中外製薬株式会社 | 5-置換-2-フェニルアミノ-ベンズアミド類の製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101190912B1 (ko) * | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| WO2012020742A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| US20130123255A1 (en) * | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
| CN109988105A (zh) * | 2014-01-27 | 2019-07-09 | 天津滨江药物研发有限公司 | 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法 |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| KR20230122174A (ko) * | 2020-07-22 | 2023-08-22 | 추가이 세이야쿠 가부시키가이샤 | 아릴 아마이드 유도체를 포함하는 조성물 |
-
2020
- 2020-07-22 WO PCT/JP2020/028575 patent/WO2022018875A1/ja not_active Ceased
- 2020-07-22 JP JP2022538564A patent/JPWO2022018875A1/ja active Pending
-
2021
- 2021-07-21 KR KR1020210095267A patent/KR102550455B1/ko active Active
- 2021-07-26 JP JP2021121960A patent/JP7168734B2/ja active Active
-
2022
- 2022-10-27 JP JP2022172687A patent/JP2023011759A/ja not_active Ceased
-
2023
- 2023-06-26 KR KR1020230081877A patent/KR20230098762A9/ko active Pending
-
2026
- 2026-03-18 JP JP2026044825A patent/JP2026102816A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028426A1 (ja) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| WO2006011466A1 (ja) | 2004-07-26 | 2006-02-02 | Chugai Seiyaku Kabushiki Kaisha | Mek阻害物質としての5-置換-2-フェニルアミノ-ベンズアミド類 |
| WO2014081024A1 (ja) | 2012-11-26 | 2014-05-30 | 中外製薬株式会社 | 5-置換-2-フェニルアミノ-ベンズアミド類の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026102816A (ja) | 2026-06-23 |
| JP7168734B2 (ja) | 2022-11-09 |
| WO2022018875A1 (ja) | 2022-01-27 |
| JP2022145416A (ja) | 2022-10-04 |
| JPWO2022018875A1 (cg-RX-API-DMAC7.html) | 2022-01-27 |
| KR20220012195A (ko) | 2022-02-03 |
| JP2023011759A (ja) | 2023-01-24 |
| KR20230098762A (ko) | 2023-07-04 |
| KR20230098762A9 (ko) | 2024-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102473971B1 (ko) | 항종양 활성을 갖는 아릴 아마이드 유도체 | |
| KR102566299B1 (ko) | 아릴 아마이드 유도체를 포함하는 조성물 | |
| KR20230098762A (ko) | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의치료 또는 예방용 의약 조성물 | |
| KR102671612B1 (ko) | 아릴아마이드 유도체의 제조 방법 | |
| HK40073328A (en) | Arylamide derivative having antitumor activity | |
| HK40073328B (en) | Arylamide derivative having antitumor activity | |
| HK40084009B (en) | Composition containing arylamide derivative | |
| EA047579B1 (ru) | Производное ариламида, обладающее противоопухолевой активностью | |
| HK40084009A (en) | Composition containing arylamide derivative | |
| EA046648B1 (ru) | Композиция, содержащая производное ариламида | |
| HK40103401A (en) | Method for producing arylamide derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20210721 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20221130 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20210721 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20221130 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20210721 Patent event code: PA03021R01I Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230103 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230403 |
|
| A107 | Divisional application of patent | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20230626 Patent event code: PA01071R01D |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230628 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230628 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |